Cencora delivered strong quarterly results and guidance upgrades, but expectations need to be moderated as these results ...

Cencora COR saw a positive improvement to its Relative Strength (RS) Rating on Tuesday, rising from 70 to 78. Please watch ...

Cencora, Inc. earns a Buy rating with a $337 fair value. Learn how its specialty drug focus and strategic investments drive ...

Healthcare distributor Cencora (NYSE:COR) reported Q2 CY2025 results beating Wall Street’s revenue expectations, with sales ...

Readers hoping to buy Cencora, Inc. (NYSE:COR) for its dividend will need to make their move shortly, as the stock is about to trade ex-dividend. The ex-dividend date is one business day before a ...

Cencora, Inc. (NYSE:COR) on Wednesday reported third-quarter 2025 sales increased 8.7% to $80.66 billion, beating the ...

Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. An announcement from Cencora ( (COR)) is now available. On August 6, 2025, Cencora ...

Q3 2025 Earnings Call Transcript August 6, 2025 Cencora, Inc. beats earnings expectations. Reported EPS is $4, expectations were $3.85. Operator: Hello, everyone, and thank you for joining the Cencora ...

U.S. drug distributor Cencora raised its annual profit forecast on Wednesday after posting quarterly earnings that topped ...

Whales with a lot of money to spend have taken a noticeably bullish stance on Cardinal Health. If we consider the specifics of each trade, it is accurate to state that 60% of the investors opened ...

Shares of Cencora Inc. COR shed 2.93% to $283.78 Wednesday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index SPX rising 0.73% to 6,345.06 and ...

The company demonstrated significant growth in operating income and earnings per share (EPS), particularly within the U.S. Healthcare Solutions segment. Despite some challenges in the International ...